| アブストラクト | BACKGROUND: Although chronic kidney disease (CKD) is associated with high multimorbidity, polypharmacy, morbidity and mortality, existing classification systems (mild to severe, usually based on estimated glomerular filtration rate, proteinuria or urine albumin-creatinine ratio) and risk prediction models largely ignore the complexity of CKD, its risk factors and its outcomes. Improved subtype definition could improve prediction of outcomes and inform effective interventions. METHODS: We analysed individuals >/=18 years with incident and prevalent CKD (n = 350,067 and 195,422 respectively) from a population-based electronic health record resource (2006-2020; Clinical Practice Research Datalink, CPRD). We included factors (n = 264 with 2670 derived variables), e.g. demography, history, examination, blood laboratory values and medications. Using a published framework, we identified subtypes through seven unsupervised machine learning (ML) methods (K-means, Diana, HC, Fanny, PAM, Clara, Model-based) with 66 (of 2670) variables in each dataset. We evaluated subtypes for: (i) internal validity (within dataset, across methods); (ii) prognostic validity (predictive accuracy for 5-year all-cause mortality and admissions); and (iii) medications (new and existing by British National Formulary chapter). FINDINGS: After identifying five clusters across seven approaches, we labelled CKD subtypes: 1. Early-onset, 2. Late-onset, 3. Cancer, 4. Metabolic, and 5. Cardiometabolic. Internal validity: We trained a high performing model (using XGBoost) that could predict disease subtypes with 95% accuracy for incident and prevalent CKD (Sensitivity: 0.81-0.98, F1 score:0.84-0.97). Prognostic validity: 5-year all-cause mortality, hospital admissions, and incidence of new chronic diseases differed across CKD subtypes. The 5-year risk of mortality and admissions in the overall incident CKD population were highest in cardiometabolic subtype: 43.3% (42.3-42.8%) and 29.5% (29.1-30.0%), respectively, and lowest in the early-onset subtype: 5.7% (5.5-5.9%) and 18.7% (18.4-19.1%). MEDICATIONS: Across CKD subtypes, the distribution of prescription medication classes at baseline varied, with highest medication burden in cardiometabolic and metabolic subtypes, and higher burden in prevalent than incident CKD. INTERPRETATION: In the largest CKD study using ML, to-date, we identified five distinct subtypes in individuals with incident and prevalent CKD. These subtypes have relevance to study of aetiology, therapeutics and risk prediction. FUNDING: AstraZeneca UK Ltd, Health Data Research UK. |
|---|
| ジャーナル名 | EBioMedicine |
|---|
| Pubmed追加日 | 2023/3/2 |
|---|
| 投稿者 | Dashtban, Ashkan; Mizani, Mehrdad A; Pasea, Laura; Denaxas, Spiros; Corbett, Richard; Mamza, Jil B; Gao, He; Morris, Tamsin; Hemingway, Harry; Banerjee, Amitava |
|---|
| 組織名 | Institute of Health Informatics, University College London, London, UK.;Institute of Health Informatics, University College London, London, UK; British;Heart Foundation Data Science Centre, Health Data Research UK, London, UK.;Imperial College Healthcare NHS Trust, London, UK.;Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, London,;UK.;Institute of Health Informatics, University College London, London, UK; Health;Data Research UK, University College London, London, UK.;Institute of Health Informatics, University College London, London, UK; Barts;Health NHS Trust, London, UK; University College London Hospitals NHS Trust,;London, UK. Electronic address: ami.banerjee@ucl.ac.uk. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36857859/ |
|---|
